Galderma is a leading American-Swiss pharmaceutical company specializing in dermatological treatments and skin care products. With a unique heritage in dermatology and decades of innovation, Galderma is dedicated to advancing dermatology for every skin story. The company operates in the dermatology industry and is part of the pharmaceutical sector. Galderma has a global presence, with operations in 40 countries and headquarters in Switzerland. They have achieved major health authority approvals, funded numerous clinical trials, and trained over 100,000 aesthetics healthcare professionals. Galderma has a rich history, including acquisitions, divestments, and the launch of innovative products.

M Owen

Galderma

RVL Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas in the United States, Argentina, and Hungary. The company is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults. The company was formerly known as Osmotica Pharmaceuticals plc and changed its name to RVL Pharmaceuticals plc in January 2022. RVL Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.

RVL Pharmaceuticals plc

Galderma is the leading company solely dedicated to skin and advancing the future of dermatology.We deliver an innovative, science-based portfolio of sophisticated brands and services across Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Through trusted partnerships with healthcare professionals, we ensure to meet individual consumer and patient needs with superior outcomes.

Metric
Company Name	Galderma	RVL Pharmaceuticals plc
Symbol		RVLP
MSH ID	COM:GALDERMA	COM:RVLPHARMA
Market	PRIVATE	STOCKS
Sector	Pharmaceuticals	Healthcare
Industry	Dermatology	Biotechnology
Country	CH	US
Stage	Post-IPO Secondary
Employee Count	5.94K	125
Website	galderma.com	rvlpharma.com
LinkedIn	galderma-	rvl-pharmaceuticals-inc
Founders

Metric
Market Cap		3.14M
Enterprise Value
Monthly Web Traffic	108.32K	1.19K
Web Traffic Growth	0.00	-0.82
Valuation
Raised Capital	1.44B

Metric
Revenue		49.72M
Revenue (LTM)
Revenue (NTM)
Gross Profit		40.27M
EBITDA		-36.19M
Operating Income		-45.68M
Net Income		-51.69M
EPS		-0.58
Diluted EPS		-0.58
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin		0.75
Operating Profit Margin		-1.56
EBITDA Margin		-0.73
Net Profit Margin		-1.85
Return on Equity		-1.55
Return on Assets		-0.80
Return on Capital Employed		-3.38

COM:GALDERMA

Galderma

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio		-0.04
P/B Ratio		0.17
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio		0.09
EV Multiple		0.99

Metric
Days Sales Outstanding		19.10
Days Payables Outstanding		98.98
Days Inventory Outstanding		53.05
Operating Cycle		72.15
Cash Conversion Cycle		-26.83
Asset Turnover		0.43

Metric
Operating Cash Flow		-37.81M
Free Cash Flow		-38.56M
Cash Flow to Debt		-0.76
Operating Cash Flow/Sales		-1.20
Free Cash Flow Yield		-15.11

Metric
Cash & Equivalents		44.54M
Accounts Receivable		-898K
Inventory		784K
Goodwill		55.85M
Debt to Capitalization		0.78
Debt to Assets		0.68
Current Ratio		0.38
Quick Ratio		0.31

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue		0.06
R&D to Revenue		0.08
SG&A to Revenue